Search

Your search keyword '"Sinha, Smeeta"' showing total 389 results

Search Constraints

Start Over You searched for: Author "Sinha, Smeeta" Remove constraint Author: "Sinha, Smeeta"
389 results on '"Sinha, Smeeta"'

Search Results

2. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial

5. Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort

6. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

8. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

9. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

15. Description and cross-sectional analyses of 25,880 adults and children in the UK National Registry of Rare Kidney Diseases cohort

16. WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL

17. WCN24-1688 SELF-REPORTED QUALITY OF LIFE IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS DELINEATED BY CKD STAGE: A REAL-WORLD, MULTI-COUNTRY SURVEY

18. WCN24-1680 PREVALENCE AND CLINICAL CHARACTERISTICS OF KIDNEY TRANSPLANTS IN COMPLEMENT 3 GLOMERULOPATHY PATIENTS: RESULTS FROM A REAL-WORLD, MULTI-COUNTRY SURVEY

22. Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined‐up care for diabetes, chronic kidney disease, and heart failure.

23. Association of deprivation and its individual domains on outcomes in people with chronic kidney disease.

26. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

31. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

36. Safely reducing haemodialysis frequency during the COVID-19 pandemic

42. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

43. Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes : An Individual-Participant Data Meta-Analysis.

Catalog

Books, media, physical & digital resources